INTERVIEWS: NFL Players Discuss the Rare, Chronic, and Underserved Causes that Mean the Most to Them (Pt. 3)
https://pixabay.com/en/american-football-football-sports-1666276/

INTERVIEWS: NFL Players Discuss the Rare, Chronic, and Underserved Causes that Mean the Most to Them (Pt. 3)

Before you read on, make sure to check out: Part 1 of our article: Green Bay Packers' Shemar Jean-Charles and Los Angeles Chargers' Storm Norton discuss why they raise Alzheimer's disease…

Continue Reading INTERVIEWS: NFL Players Discuss the Rare, Chronic, and Underserved Causes that Mean the Most to Them (Pt. 3)

The European Commission Has Approved Pembrolizumab (Keytruda) to Treat Resected Stage IIB and IIC Melanoma

According to a press release by Merck & Co. issued on June 24, the European Commission has approved the use of adjuvant Pembrolizumab to treat resected stage IIB/C melanoma. "Adjuvant"…

Continue Reading The European Commission Has Approved Pembrolizumab (Keytruda) to Treat Resected Stage IIB and IIC Melanoma
An Innocent-Looking Shadow on Her Thumbnail Turned Out to be Subungual Melanoma
Source: https://pixabay.com/en/thumb-up-like-sign-hand-ok-good-441938/

An Innocent-Looking Shadow on Her Thumbnail Turned Out to be Subungual Melanoma

Maria’s message is: “when in doubt, get a biopsy." Ten years ago, Maria Sylvia noticed a vertical streak on her thumbnail that at the time she thought was “cool." She…

Continue Reading An Innocent-Looking Shadow on Her Thumbnail Turned Out to be Subungual Melanoma
Recurrence-Free Survival in High-Risk Stage III Melanoma With Pembrolizumab Confirmed by Long Term Follow-up
source: pixabay.com

Recurrence-Free Survival in High-Risk Stage III Melanoma With Pembrolizumab Confirmed by Long Term Follow-up

  According to a recent report in the Journal of Clinical Oncology, over one thousand patients with high-risk stage III melanoma were included in the Keynote-054 clinical trial (NCT02362594). The…

Continue Reading Recurrence-Free Survival in High-Risk Stage III Melanoma With Pembrolizumab Confirmed by Long Term Follow-up
First Patient Dosed in Phase 2 Trial to Evaluate AU-011 for Choroidal Melanoma
cocoparisienne / Pixabay

First Patient Dosed in Phase 2 Trial to Evaluate AU-011 for Choroidal Melanoma

  Recently, clinical-stage biopharmaceutical company Aura Biosciences announced a Phase 2 clinical trial to determine the safety, efficacy, and tolerability of AU-011 for patients with choroidal melanoma. Currently, Aura Biosciences…

Continue Reading First Patient Dosed in Phase 2 Trial to Evaluate AU-011 for Choroidal Melanoma